Close menu




September 22nd, 2022 | 14:01 CEST

Uniper and Kion in shock, partial mobilization at BASF and Meta Materials

  • Technology
  • Innovations
  • hightech
  • chemicals
Photo credits: pixabay.com

For the first time in recent history, an announced appearance by Putin did not take place. In the morning yesterday, the news finally rang out that Russia had been so afraid of for the past few weeks: Putin announced partial mobilization. It likely involves an additional 300,000 troops who will now go into mobilization. News about the war apparently only impacts the stock market if it also conceals economic news, because the market rose despite expected escalations. However, the consensus now seems to be that a sharp slowdown in economic growth is expected worldwide. Currently, many stocks are adjusting to a new view: interest rates are back, so capitalization models are recalculating, especially for growth stocks. Where should attention be paid now?

time to read: 5 minutes | Author: André Will-Laudien
ISIN: UNIPER SE NA O.N. | DE000UNSE018 , KION GROUP AG | DE000KGX8881 , Meta Materials Inc. | US59134N1046 , BASF SE NA O.N. | DE000BASF111

Table of contents:


    BASF - The acid test is still to come

    Whenever the DAX takes a breath of morning air, BASF shares make smaller daily gains. Overall, this means that the share price has been able to hold above the EUR 40 mark for weeks. Technical support lines, which date back to the pandemic correction in 2020, are also located here. After all, BASF shares have already doubled once without today's gas problems, namely from March 2020 to February 2021.

    Analytically, the Ludwigshafen-based chemical giant is more attractive than ever. That is because, in all likelihood, sales will even be able to increase in 2022, and it should also be possible to pass on prices to chemical precursors on the market as the increased cost pressure runs through the entire sector. After all, BASF is also the world market leader for some products and can make announcements. The pressure is then passed on to the next intermediate customer.

    With a P/E ratio of 7.7 and a dividend yield of over 8%, BASF shares remain a clear frontrunner in the valuation parameters. However, the shortage of gas in Germany, which has not yet been completely eliminated, could continue to be a burden. If the gas storage facilities were to empty again in winter, industrial capacities would probably also have to be curtailed. 75% of all chemical processing runs on gas, so BASF's dependence could not be greater. The share should continue to be actively monitored, and a dividend cut in the coming years should be considered. If the gas front eases, the stock would be an immediate "must buy."

    Meta Materials - An extensive collection of good ideas

    In order to be at the forefront of today's high-tech industry, one needs good thinking in the development department and management that recognizes trends early on and takes the lead in bringing new ideas to market by patenting them. Even though META®-Materials' solutions address entire industries, some with only minor technical features, the main thrusts can be divided into the three areas of holography, lithography and wireless sensor technology with strong IT networking. Importantly, the technologies are capable of further development with the help of artificial intelligence, thus affecting entire sectors in the high-tech industry. In days of energy scarcity and increasing industrial efficiencies, process efficiency is coming back into the spotlight. Especially in automotive engineering or medical and chip technology, surface coatings and flexible materials are in demand that consume little energy and offer progress in terms of safety. Developments such as autonomous driving, remote production or augmented reality would be impossible without smart components. Ultimately, machines are enabled to function better in sensitive areas than humans with their natural performance limits.

    In the field of e-mobility, META® recently joined forces with Coulometrics to optimize energy cells. In the medical sector, META® is working in early stroke detection to improve the resolution and transmission speed of portable scanners. The most important technologies are found on glass, structural components and surfaces; they are also used, for example, in armor for the special design of camouflage caps or the integration of "invisible" antennas. The development of these high-performance materials has now generated sales of USD 3.3 million in the second quarter. Although this is still very little, it is nothing out of the ordinary for a company focused on research and development. Once an idea has been developed into a blockbuster, its widespread use in the industry could quickly bring substantial licensing revenues into the Company's coffers, taking it into a whole new category.

    Due to the last capital increase in June, the cash box should still be well filled because currently, it is becoming increasingly difficult to raise growth capital quickly. The buying mood of NASDAQ investors has not yet fully returned after the recent price corrections. At a price of around EUR 0.80, the 360.84 million shares are currently valued at EUR 288 million. For the high-tech share, it can go up again quickly with good news. The value is very liquid and easily tradable.

    CEO George Palikaras will report live on the latest progress at Meta Materials on September 27, 2022, at 7:30 pm at the 4th International Investment Forum. Click here for free registration.

    Uniper and Kion - This is what capitulation looks like

    A sell-off with no end in sight - this is how one could title the charts of Uniper and Kion. Both stocks are currently not very popular with investors. At Uniper, the almost complete nationalization ensures a total dilution of the existing shareholders. At present, it is even doubtful whether the business model of free gas trading can still be implemented in Germany. It seems strange that gas, one of the world's most liquid commodities, is degenerating into political madness in Germany. Regulatory changes in the form of state price limits would have to be made before private entrepreneurship could flourish again. As mentioned above, BASF business is also hanging by a thread on gas availability. In the long term, this could weigh heavily on the German economy.

    Kion was still at just under EUR 100 at the beginning of the year and can now be bought at EUR 20. The market capitalization has now quintupled to EUR 2.75 billion in 9 months of the current year. The logistics equipment supplier expects a sharp drop in profits, with adjusted operating profit (EBIT) down EUR 200 to 300 million YOY. High inflation, increased material costs and wages, and supply bottlenecks are putting pressure on the world's largest forklift manufacturer, as passing on the high costs does not fit into its long-term contractual agreements with key customers. An operating loss of EUR 190 million is now expected.

    Uniper, like Kion, is currently not an investment security but rather a casino stock. However, while the business model must be doubted in the case of Uniper, Kion can probably stabilize again through medium-term price adjustments in buying and selling. Nevertheless, buy only when upward momentum sets in.


    The stock market will continue to react to the difficult economic situation for some time. For this, the prices still appear quite high. Therefore, expect further downward corrections, but medium-term entry opportunities will also become apparent. BASF and Meta Materials are already attractive, while Uniper and Kion should be watched closely to see what happens to their prices.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Armin Schulz on October 4th, 2022 | 10:58 CEST

    JinkoSolar, TubeSolar, Encavis - Shares for the energy turnaround

    • agritech
    • renewableenergies
    • Technology

    The phase-out of fossil energy generation is a done deal in Germany, but there is still a long way to go. Germany's share of renewable energies in electricity generation was 42.4% in 2021. However, this covered only 19.7% of Germany's energy consumption. Since the flare-up of the Ukraine crisis, the expansion of renewable energies is to be accelerated. A balanced mix is essential. Spring and summer are the main times for solar power, while in fall and winter, when the days are shorter, wind power is the primary source of electricity. If we want to achieve the 2030 targets, a massive expansion is essential. Today we take a look at three renewable energy companies.

    Read

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read